BDSX Overview

Biodesix, Inc. is a diagnostic solutions company. It offers two tests (Nodify Lung tests) that assess the risk of cancer in lung nodules and three tests (IQLung tests) that provide treatment guidance after a lung cancer diagnosis. Nodify CDT and Nodify XL2 tests, marketed as Nodify Lung Nodule Risk Assessment, assess the lung nodule's risk of lung cancer to help identify the appropriate treatment pathway. The Nodify CDT test is a blood-based test that detects the presence of seven autoantibodies associated with the presence of tumors. The Nodify XL2 test is a blood-based proteomic test that evaluates the likelihood that a lung nodule is benign to help identify patients that may benefit from surveillance imaging. GeneStrat ddPCR, GeneStrat NGS and VeriStrat tests, marketed as part of its IQLung testing strategy, are used following diagnosis of lung cancer to detect the presence of mutations in the tumor and the state of the patient’s immune system to help guide treatment decisions.

Wall Street analysts forecast BDSX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BDSX is30.00 USD with a low forecast of 20.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Biodesix Inc revenue for the last quarter amounts to 28.75M USD, increased 40.76

Biodesix Inc. EPS for the last quarter amounts to -0.49 USD, decreased -56.25

Biodesix Inc (BDSX) has 334 emplpoyees as of April 21 2026.

Today BDSX has the market capitalization of 133.11M USD.